Welcome to our dedicated page for Trilogy Metals SEC filings (Ticker: TMQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Trilogy Metals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Trilogy Metals's regulatory disclosures and financial reporting.
Trilogy Metals Inc. reported a director equity award on a Form 4. On 12/11/2025, the director received a stock option to buy 50,000 common shares of Trilogy Metals.
The option has an exercise price of $4.61 per share, which was converted from a Canadian exercise price of C$6.35 using an exchange rate of C$1.3774 = US$1.00. The option is exercisable starting 12/11/2025 and expires on 12/10/2030. Following this grant, the director beneficially owns 50,000 derivative securities directly.
Trilogy Metals Inc. director William I. Iggiagruk Hensley reported a stock option grant. On 12/11/2025, he received a director stock option to buy 50,000 common shares of Trilogy Metals at an exercise price of $4.61 per share. The option becomes exercisable on 12/11/2025 and expires on 12/10/2030, giving a five-year window to exercise once it is vested. The U.S. dollar exercise price was calculated from a Canadian dollar exercise price of C$6.35 using an exchange rate of C$1.3774 = US$1.00.
Trilogy Metals Inc. reported a director stock option grant for William Beckwith Hayden. On 12/11/2025, he was awarded options to buy 50,000 common shares of Trilogy Metals.
The options have an exercise price of $4.61 per share, which was converted from a Canadian exercise price of C$6.35 using an exchange rate of C$1.3774 = US$1.00. The options become exercisable on 12/11/2025 and expire on 12/10/2030. After this grant, he beneficially owns 50,000 derivative securities directly.
Trilogy Metals Inc. (TMQ) reported an insider equity award for director James Gowans. On 12/11/2025, he received a director stock option covering 50,000 common shares at an exercise price of $4.61 per share. The option is exercisable starting 12/11/2025 and expires on 12/10/2030.
The exercise price was converted from a Canadian exercise price of C$6.35 using an exchange rate of C$1.3774 = US$1.00, so the award is valued and reported in U.S. dollars for disclosure purposes.
Trilogy Metals Inc. (TMQ) reported an insider equity transaction by its Vice President and Chief Financial Officer, Elaine Sanders. On December 7, 2025, 183,334 restricted stock units (RSUs) were converted into common shares at a price of $0 per share, reflecting the vesting and settlement of equity awards rather than an open‑market purchase.
Following this transaction, Sanders directly beneficially owns 3,332,895 common shares of Trilogy Metals. The RSUs originated from a grant on December 7, 2023 that vests in three equal installments on December 7, 2023, December 7, 2024, and December 7, 2025, aligning her compensation with long‑term shareholder value.
Trilogy Metals Inc. reported an insider equity transaction by its President and CEO, Tony Giardini. On December 7, 2025, he acquired 366,668 common shares of Trilogy Metals through the settlement of previously granted restricted stock units (RSUs), coded as an “M” transaction. After this transaction, he directly beneficially owned 8,698,728 common shares.
The RSUs originated from a grant made on December 7, 2023 that vested in three equal installments: one-third on December 7, 2023, one-third on December 7, 2024, and one-third on December 7, 2025. Following the conversion of 366,668 RSUs into common shares at an exercise price of $0, the reported RSU balance in the derivative securities table is 0, reflecting full settlement of this particular grant.
Trilogy Metals Inc. director reports option exercise, share sales, and gift of shares. On 12/05/2025, a director exercised an employee stock option for 50,000 common shares at a U.S. dollar exercise price of $1.82, converted from C$2.52 using an exchange rate of C$1.3860 = US$1.00.
The director then sold 20,000 common shares at $4.73 and a further 50,000 common shares at a weighted average price of $4.77, based on Canadian dollar prices between C$6.55 and C$6.701 converted at the same exchange rate. In addition, the director made a gift of 45,000 common shares at a price of $0.
Following these transactions, the director held 35,000 common shares directly and 252,000 common shares indirectly through a family trust, and held no remaining employee stock options from this grant.
Trilogy Metals Inc. director reports new deferred share units grant
A director of Trilogy Metals Inc. (TMQ) filed a Form 4 reporting a grant of 3,428.772 Deferred Share Units (DSUs) on 12/01/2025 at a price of $0 per unit. After this transaction, the director beneficially owns 555,079.536 derivative securities in the form of DSUs, held directly.
The DSUs were issued on a non-discretionary basis under elections made by plan participants before the start of the current fiscal year. The DSUs vest immediately, but the underlying common shares will not be issued, and the holder will not have voting or dispositive rights in those shares, until the director’s service with the company ends. The grants will expire no later than 90 days after the director’s termination date.
Trilogy Metals Inc. reported a routine insider equity transaction for a director on a Form 4. On 12/01/2025, the director received 3,551.228 Deferred Share Units (DSUs) at an exercise price of $0, coded as an acquisition. Following this grant, the director beneficially owns 644,091.192 derivative securities in the form of DSUs, held directly.
The DSUs were issued on a non-discretionary basis under elections made before the start of the current fiscal year. The DSUs vest immediately, but the underlying common shares will only be issued after the director’s service with Trilogy Metals ends, and no voting or sale rights apply to those shares until that time. The grants will expire no later than 90 days after the director’s termination date.
Trilogy Metals Inc.12/01/2025, he received 3,122.632 Deferred Share Units (DSUs) under a non-discretionary plan, at an exercise price of $0 per unit. After this grant, he beneficially owns 614,032.397 DSUs in total.
The DSUs vest immediately, but the underlying common shares are not issued, and he has no voting or dispositive rights over those shares, until his service as a director ends. The DSU grants will expire no later than 90 days after his termination date. This filing reflects routine director compensation in equity form rather than a market purchase or sale of Trilogy Metals shares.